BARD1 Life Sciences (ASX:BD1) - CEO, Leearne Hinch
CEO, Leearne Hinch
Source: BARD1 Life Sciences
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • BARD1 Life Sciences (BD1) advances sales, business development and commercialisation activities over the June quarter
  • BD1 experienced increased demand for its hTERT ICC test, pocketing $184,000 in cash receipts compared with $42,000 in the March quarter
  • The company also launched its EXO-NET product, reported positive feedback from its research partners regarding the tech’s speed, purity and yield
  • BARD1 ended the June period with a cash balance of $5 million
  • Shares closed down 5.80 per cent to $1.38 each

BARD1 Life Sciences (BD1) has reported advances across its sales, business development and commercialisation activities over the June quarter.

hTERT attracts increased revenue in Q4

Notably, the company experienced a rise in demand for its hTERT ICC test, which works to detect potential biomarkers for cancer in urine samples.

BD1 said revenues for the 2021 financial year had grown by almost 30 per cent over the quarter, compared to the 2020 financial year.

Accordingly, the company pocketed $184,000 in cash receipts for the period, up from $42,000 in the March quarter.

The company attributes the upwards trend to a recovery in the United States’ “routine” pathology market following the onset of COVID-19, and the onboarding of new laboratories in the US as well as a South Korean distributor.

Discussions with distributors in Greece, Sweden and Israel are under way.

EXO-NET commercialisation

The fourth quarter also heralded the launch of BD1’s research-use-only EXO-NET technology.

The product works to isolate exosomes — a specific type of tiny particle released by most cells, including cancer cells, into bodily fluids that can be used to diagnose and treat diseases such as cancer.

BARD1 presented EXO-NET at the virtual International Society for Extracellular Vesicles in May and is signed on as a platinum sponsor of the Australia & New Zealand Society for Extracellular Vesicles on the Gold Coast in November.

BD1 continues to evaluate the product in partnership with leading research institutes in Australia and overseas.

To date, feedback on the tech’s speed, purity and yield advantages has reportedly been positive, foreshadowing its future use in exosome research applications.

Other updates

Meanwhile, BD1 used the fourth quarter to progress feasibility studies for the development of its SubB2M blood tests for breast and ovarian cancers, with a new breast cancer test manuscript submitted for publication.

Further, the company filed two new patent applications protecting EXO-NET and SubB2M, and was granted two patents covering its antibody tests in the US and South Korea.

Finances

Finally, the June period saw BD1 accept a research and development refund to the tune of $644,000 for the prior fiscal year.

The company ended the period with a cash balance of $5 million.

Shares closed 6.1 per cent lower at $1.38 each.

BD1 by the numbers
More From The Market Online

Universal Biosensors surges 60% on FDA approval for Class II device

Universal Biosensors shares surged 60% following the attainment of US Food and Drug Administration and Clinical…

Vitura joint venture prescribes shrooms for therapeutic use in Australian-first

In an Australian-first pharmaceutical achievement, Vitura Health Limited has announced the first ever shipment of 'shrooms'…

Mesoblast (ASX:MSB) completes $97M funding round heading into Q2

Mesoblast (ASX:MSB) has completed its pro-rata accelerated non-renounceable entitlement offer, launched on December 4, 2023.

Recce Pharma (ASX:RCE) kicks-off dosing for next cohort of UTI trial

Recce Pharmaceuticals (ASX: RCE) has announced the successful dosing of the latest group of human participants…